Tag: immunotherapy

Search News
Categories
Archives
New drug combination doubles survival for people with bladder cancer

25th October 2023

Clinical trial results from BCI and Barts NHS trust provide new hope for people with bladder cancer.

Read more

The REMODEL project: Remodelling tumour microenvironments to improve immunotherapy

12th October 2022

Professor Fran Balkwill from Barts Cancer Institute at Queen Mary University of London has received a UK Research and Innovation (UKRI) Frontier Research grant of over £2 million to investigate the most effective ways to remodel cancers to enhance the effects of immunotherapy.

Read more

In conversation with Professor Marco Gerlinger

20th May 2022

This International Clinical Trials Day, we spoke with Professor Marco Gerlinger. Professor Gerlinger and his team’s laboratory research focuses on understanding and overcoming drug resistance in bowel and gastro-oesophageal cancers, and identifying new and more effective ways to treat these cancers using immunotherapies and combination therapies.

Read more

Research highlighted in ASCO annual report on progress against cancer

2nd February 2021

Research led by Professors Peter Schmid and Thomas Powles from Barts Cancer Institute, Queen Mary University of London, has been selected by the American Society of Clinical Oncology (ASCO) for inclusion in the Clinical Cancer Advances 2021, the Society’s annual review of progress against cancer. The notable studies, which investigated the use of immunotherapy in the treatment of triple negative breast cancer and advanced bladder cancer, are featured as two of many remarkable milestones in clinical cancer research and care.

Read more

CAR T cell therapy for pancreatic cancer

22nd January 2021

Researchers from Barts Cancer Institute, Queen Mary University of London, have identified a protein that may represent a novel therapeutic target for the treatment of pancreatic cancer. Using this protein as a target, the team successfully created a CAR T cell therapy – a type of immunotherapy – that killed pancreatic cancer cells in a pre-clinical model.

Read more

Novel insights into graft-versus-host disease

13th October 2020

Research led by Barts Cancer Institute, Queen Mary University of London, has identified a subset of immune cells involved in site-specific tissue damage in cancer patients who have developed harmful graft-versus-host disease after stem cell transplantation. The insights gained from the study may help to define new targets for more selective approaches to prevent or treat this condition in patients who have received a stem cell transplant.

Read more

Search News
Categories
Archives